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ABSTRACT
The MutL family of mismatch repair proteins belongs to the GHKL class of ATPases, which 
contains also type II topoisomerases, HSP90 and histidine kinases. The nucleotide binding domains 
of these polypeptides are highly conserved, but this similarity has failed to help us understand the 
biological role of the ATPase activity of the MutL proteins in mismatch repair. hMutLα is a 
heterodimer of the human MutL homologues hMLH1 and hPMS2 and we decided to exploit its 
asymmetry to study this function. We now show that although the two subunits contribute differently 
to the ATPase activity of the heterodimer, hMutLα variants in which one subunit was able to bind – 
but not hydrolyze – ATP, displayed similarly reduced mismatch repair activities in vitro. In contrast, 
variants in which either subunit was unable to bind the nucleotide were inactive. Mutation of the 
catalytic sites of both subunits abolished repair without altering the ability of these peptides to 
interact with one another. As the binding of the nucleotide in hMutLα was not required for the 
formation of ternary complexes with the mismatch recognition factor hMutSα bound to a 
heteroduplex substrate, we propose that the ATPase activity of hMutLα is required downstream from 
this process. 
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INTRODUCTION
DNA mismatch repair (MMR) is a highly conserved process that removes nucleotides 
misincorporated into the newly-synthesized DNA strand during replication or recombination (1,2). 
Unlike other DNA repair pathways, correction of biosynthetic errors requires not only that non-
canonically paired bases be recognized, but also that the repair system be able to differentiate 
between the template and the newly-synthesized DNA strand, such that it can direct the correction 
process to the latter. In E.coli, mismatched base pairs and short insertion-/deletion loops (IDL) are 
recognized by the MutS homodimer, which initiates the repair process by recruiting the remaining 
members of the repairosome: the MutL homodimer, the strand discrimination factor MutH and DNA 
helicase II (UvrD), as well as one of several exonucleases (both 5’→3 and 3→5), DNA polymerase 
III holoenzyme and DNA ligase. The MutL protein plays a key role in coordinating this process. It 
activates the cryptic endonuclease activity of MutH (3-5), which then nicks the newly-synthesized 
DNA strand. This reaction is enabled by the transient undermethylation of GATC sequences in 
newly-synthesized DNA and by the ability of MutH to incise only the unmethylated strand. MutL 
also appears to be responsible for directional loading of DNA helicase II at the site of the nick (6,7). 
The displaced DNA is exonucleolytically degraded and the removed stretch is then resynthesized by 
the replicative DNA polymerase (see (8,9) for review). In spite of the fact that the MMR pathway of
 E.coli could be reconstituted from the purified individual components (10), our knowledge of the 
molecular mechanism of the process is limited. This is especially true for the MutL protein, the role 
of which is particularly enigmatic. What is clear is that its transactions, like those of MutS, are 
governed by ATP binding and/or hydrolysis. This was first implied by experiments of Grilley et al. 
(11), who showed that MutL and MutS interact on a heteroduplex substrate in an ATP-dependent 
manner, and from in vivo studies of Aronshtam and Marinus (12), who showed that MutL alleles 
carrying single amino acid substitutions in the vicinity of the ATP binding domain of MutL were 
unable to complement the MMR defect of a mutL– strain. More recently, the N-terminal domain of 
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MutL could be shown to contain four short sequence motifs that are found also in the type II 
topoisomerases, the HSP90 heat shock proteins and histidine kinases (Fig. 1a) (13,14). Structural 
analyses of members of all four families revealed that these proteins share a novel nucleotide-
binding fold and suggested an important role for the invariant residues in binding and/or hydrolysis 
of ATP (see (15) for review). Thus, this superfamily of proteins, known as GHKL ATPases, is likely 
to have evolved from a common ancestor. However, as illustrated by the divergent roles of these 
proteins, their common fold is a poor predictor of biological function. 
The recently-described crystal structures of LN40, the N-terminal 349 amino acid residues 
of MutL (16,17), revealed that the polypeptide folds into two α/β domains (Fig. 1a). The first (amino 
acids 20-200) harbors all four conserved motifs that form the nucleotide binding site. In the second 
domain (amino acids 224-331), a loop containing an invariant lysine residue (K307), is likely to act 
as a sensor that triggers a conformational change in the protein in response to nucleotide binding 
within the first domain. Such changes have been noted with both LN40 and the entire MutL protein 
(16). Analysis of gel filtration and sedimentation properties of the full length MutL suggested that its 
elongated structure became globular upon binding of ADPNP. More dramatically, binding of 
ADPNP triggered dimerization of LN40 in solution, as well as in crystallization experiments. The 
structure of LN40•ADPNP revealed that more than 60 amino acid residues within this domain 
became ordered and contributed to nucleotide binding or to the dimerization of the NBDs. Assuming 
that the carboxy-terminal ends of MutL remain stably associated during this time, the amino 
terminal part of MutL could function as an ATP-driven molecular gate. Type II topoisomerases 
make use of such a gate to capture a segment of duplex DNA in order to pass it through a transient 
double strand break (18) and ATP-induced dimerization of HSP90 (19) has been suggested to play a 
role in clamping the substrate polypeptides during the folding reaction (20). In addition, ATP 
binding/hydrolysis is important in the coordination of HSP90 interactions with other proteins. For 
example, HSP90 interacts with the co-chaperone p23 only in its ATP-bound form (21,22). Given 
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that MutL needs to interact with different partners, a similar role of ATP binding might be 
anticipated. Based on the observation that non-hydrolyzable ATP analogues promoted the binding of 
single-stranded DNA by MutL (17,23), it was hypothesized that the molecular gate might be used to 
clamp MutL onto DNA. In agreement with this, single stranded DNA was found to stimulate the 
very weak ATPase activity of MutL (17,24). Importantly, substitution of an arginine residue located 
within the gate (R266E) abolished both DNA binding and the stimulation of the ATPase activity 
(17).
The molecular mechanism of MMR appears to be highly conserved, as witnessed by the 
identification of MutS and MutL (but not MutH) homologues in most organisms studied to date. In 
human cells, the MutS homologues hMSH2, hMSH3 and hMSH6 form two heterodimers, hMutSα 
(hMSH2/hMSH6) and hMutSβ (hMSH2/hMSH3), which are involved in mismatch recognition (25-
28). Of the four mutL homologues (hMLH1, hPMS1, hPMS2 and hMLH3) identified to date in the 
human genome (29), hMLH1 and hPMS2 play a predominant role in MMR (30-35). The 
polypeptides encoded by these genes interact via their carboxy-terminal halves to form a stable 
heterodimer, hMutLα, which is indispensable for MMR (30,36-38). 
Germline mutations in MMR genes, such as those found in the Hereditary Non-Polyposis 
Colon Cancer (HNPCC) kindreds, predispose to cancers of the colon, endometrium and ovary (39). 
Of the nearly 300 families entered in the HNPCC database (http:/www.nfdht.nl), more than 160 carry 
mutations in the hMLH1 locus, of which about 30 % cause single amino acid changes. Many of 
these missense mutations are found in the highly conserved amino-terminal region, suggesting that 
they might affect the ATPase function of the hMLH1 protein (Fig. 1b). Interestingly, no 
corresponding mutations have been identified in the hPMS2 gene, with only four families with 
germline mutations in this locus having been described to date (33,40,41). This implies either that the
 hPMS2 gene is less prone to mutagenesis than the other HNPCC loci, that the function of hPMS2 is 
not essential for MMR due to a possible functional redundancy with another member of the MutL 
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homologue family, such as for example hMLH3 (42), or that missense mutations in hPMS2 escape 
detection, because they are phenotypically silent. We set out to address the latter hypothesis by 
studying the relative importance of the ATP binding domains of the two subunits of hMutLα in the 
MMR process. We could show previously that recombinant hMutLα, purified from baculovirus-
infected insect cells, was able to complement in vitro the MMR defect of human cell lines carrying 
mutations in either the hMLH1 or hPMS2 genes (37). In the present study, we made use of this 
system by introducing defined amino acid substitutions into the ATPase active sites of hMLH1 and 
hPMS2 and by investigating the properties of the recombinant variants in several biochemical assays.
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EXPERIMENTAL PROCEDURES
Site-Directed Mutagenesis and Production of Recombinant Baculoviruses- The Bac-To-
Bac baculovirus expression system (Invitrogen) was used according to the instructions of the 
manufacturer. Vectors for the expression of the wild type proteins have been described in (37). Site-
directed mutagenesis was used to generate vectors encoding MutL homologues that carry single 
amino substitutions in the ATP binding domain. pFastBacI-hMLH1[E34A]: Two PCR fragments 
amplified from pFastBacI-hMLH1 using the primer pairs mr_34/mr_19 and mr_18/mr_2 were used 
as templates in a second PCR step, using the mr_34/mr_2 primers. The final PCR product was 
cloned between the BamHI/PvuII sites of pFastBacI-hMLH1. pFastBacI-His6-hMLH1[E34A]:
 Two PCR fragments amplified from pFastBacI-His6-hMLH1 using the primer pairs mr_4/mr_19 and 
mr_18/mr_2 were used as templates in a second PCR step, using the mr_4/mr_2 primers. The final 
PCR product was cloned between the BamHI/PvuII sites of pFastBacI-His6-hMLH1. pFastBacI-
hMLH1[N38A]: Two PCR fragments amplified from pFastBacI-hMLH1 using the primer pairs 
mr_34/mr_21 and mr_20/mr_2 were used as templates in a second PCR step, using the mr_34/mr_2 
primers. The final PCR product was cloned between the BamHI/PvuII sites of pFastBacI-hMLH1. 
pFastBacI-His6-hMLH1[N38A]: Two PCR fragments amplified from pFastBacI-His6-hMLH1
 using the primer pairs mr_4/mr_21 and mr_20/mr_2 were used as templates in a second PCR step, 
using the mr_4/mr_2 primers. The final PCR product was cloned between the BamHI/PvuII sites of
 pFastBacI-His6-hMLH1. pFastBacI-hMLH1[D63N]: Two PCR fragments amplified from
 pFastBacI-hMLH1 using the primer pairs mr_34/mr_39 and mr_38/mr_2 were used as templates in a 
second PCR step, using the mr_34/mr_2 primers. The final PCR product was cloned between the
 BamHI/PvuII sites of pFastBacI-His6-hMLH1. pFastBacI-His6-hMLH1[D63N]: Two PCR 
fragments amplified from pFastBacI-His6-hMLH1 using the primer pairs mr_4/mr_39 and 
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mr_38/mr_2 were used as templates in a second PCR step, using the mr_4/mr_2 primers. The final 
PCR product was cloned between the BamHI/PvuII sites of pFastBacI-His6-hMLH1. pFastBacI-
His6-hPMS2: A fragment containing the 5’ end of the hPMS2 cDNA was amplified by PCR from
 pFastBacI-hPMS2 using primer mr55  and primer mr41 and cleaved with BamHI/AflII. The resulting 
fragment was cloned between the Bam HI and AflII sites of pFastBacI-hPMS2. pFastBacI-
hPMS2[E41A]: Two PCR fragments amplified from pFastBacI-hPMS2 using the primer pairs 
mr_34/mr_23 and mr_22/mr_26 were used as templates in a second PCR step, using the 
mr_34/mr_26 primers. The final PCR product was cloned between the BamHI/AflII sites of
 pFastBacI-hPMS2. pFastBacI-His6-hPMS2[E41A]: Two PCR fragments amplified from pFastBacI-
His6-hPMS2 using the primer pairs mr_34/mr_23 and mr_22/mr_26 were used as templates in a 
second PCR step, using the mr_34/mr_26 primers. The final PCR product was cloned between the
 BamHI/AflII sites of pFastBacI-hPMS2. pFastBacI-hPMS2[N45A](#139): Two PCR fragments 
amplified from pFastBacI-hPMS2 using the primer pairs mr_34/mr_25 and mr_24/mr_26 were used 
as templates in a second PCR step, using the mr_34/mr_26 primers. The final PCR product was 
cloned between the BamHI/AflII sites of pFastBacI-hPMS2. pFastBacI- His6-hPMS2[N45A]: Two 
PCR fragments amplified from pFastBacI-His6-hPMS2 using the primer pairs mr_34/mr_25 and 
mr_24/mr_26 were used as templates in a second PCR step, using the mr_34/mr_26 primers. The 
final PCR product was cloned between the BamHI/AflII sites of pFastBacI-hPMS2. pFastBacI-
hPMS2[D70N]: Two PCR fragments amplified from pFastBacI-hPMS2 using the primer pairs 
mr_34/mr_41 and mr_40/mr_42 were used as templates in a second PCR step, using the 
mr_34/mr_42 primers. The final PCR product was cloned between the BamHI/PvuII sites of
 pFastBacI-PMS2. pFastBacI-His6-hPMS2 [D70N]: An AflII/Xba I fragment of vector pFastBacI-
hPMS2[D70N] was cloned between the AflII/XbaI sites of pFastBacI-His6-hPMS2. 
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All constructs were sequenced over the entire length of the sub-cloned PCR fragments and 
checked for the presence of the desired base substitutions.
Oligonucleotides
mr_2: (5’CGGAATTCTATCTGTATGCACACTTTCCAT3’)
mr_4 : (5’CGGGATCCAAGCTCGTTCGTGGCAGGGGTT3’)
mr_18 : (5’ATGCTATCAAAGCGATGATTGAGAAC3’)
mr_19 : (5’CAGTTCTCAATCATCGCTTTGATAGC3’)
mr_20 : (5’GAGATGATTGAGGCCTGTTTAGATGC3’)
mr_21: (5’GCATCTAAACAGGCCTCAATCATCTC3’)
mr_22: (5’GCGGTAAAGGCGTTAGTAGAAAACAG3’)
mr_23: (5’CTGTTTTCTACTAACGCCTTTACCGC3’)
mr_24: (5’GGAGTTAGTAGAAGCCAGTCTGGATGC3’)
mr_25: (5’GCATCCAGACTGGCTTCTACTAACTCC3’)
mr_26: (5’GCTGCACGCTGACTGTGG3’)
mr_34: (5’GATTATTCATACCGTCCCACC3’)
mr_38: (5’CAGATCCAAAACAATGGCACC3’)
mr_39: (5’GGTGCCATTGTTTTGGATCTG3’)
mr_40: (5’GAAGTTTCAAACAATGGATGTGG3’)
mr_41: (5’CCACATCCATTGTTTGAAACTTC3’)
mr_42: (5’CACACACGGAGTCACTAGGG3’)
mr_55: (5’GCGGATCCACCATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCAACGACCGAAAACCTNGTA
    TTTTCAGGGCGAATTCGAGCGAGCTGAG3’)
48_Homo: (5’CCCAGTTGCACCCGTTTCTGGAGCCACGTTCGGTCTTAACCCGTCCAG3’)
48_∆1: (5’CCCAGTTGCACCCGTTTCTGGAGCACACGTTCGGTCTTAACCCGTCCAG 3’)
48_Bottom (5’CTGGACGGGTTAAGACCGAACGTGGCTCCAGAAACGGGTGCAACTGGG 3’)
81BG -GTGT-: (5’GACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGGCTGCAGGTTGTGCGACGGATCCCACTAGCCC
     AACTCATCC3’)
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Overexpression of the hMutLα Variants- Typically, 1.8x108 Spodoptera frugiperda (Sf9) 
cells were infected with a combination of two viruses encoding the hMLH1 and hPMS2 variants at a 
MOI of 10. 72 h after infection, cells were harvested by centrifugation (1500 rpm, 10 minutes). 
After washing the cells with 10 pellet volumes of cold PBS containing 0.5 mM PMSF, the cells were 
resuspended in 3 pellet volumes of cold buffer A (25 mM HEPES pH 8.0, 2 mM 2-
mercaptoethanol, 0.5 mM spermidine, 0.15 mM spermine, 0.5 mM PMSF and 2X CompleteEDTA
 
free
 (Roche). After incubation (20 minutes, 4 °C), the cells were lysed in a Dounce homogenizer (15 
strokes). 2 pellet volumes of a cold 50 % glycerol solution and NaCl (to a final concentration of 300 
mM) were added. After incubation (30 minutes, 4 °C, mixing), extracts were centrifuged (36000 
rpm, 30 minutes, 4 °C in a Sorvall TH-641 rotor), and stored in aliquots at 80 °C.
Purification of the hMutLα Variants- Extracts from infected Sf9 cells were diluted with an equal 
volume of buffer H (25 mM HEPES pH=7.6, 2 mM β-ME) and centrifuged (36000 rpm, 30 minutes, 
4 °C in a Sorvall TH-641 rotor). Filtered extracts (0.45 µm) were applied to a 5 ml Heparin HiTrap 
column (AP Biotech) equilibrated with a buffer H containing 150 mM NaCl and proteins were eluted 
with a raising 2 %/ml salt gradient. Pooled fractions containing the hMutLα variants were adjusted 
to 5 mM imidazol. An appropriate volume of Ni-NTA agarose (STRATAGENE) (approximately 7 
ml of a 50 % slurry per 100 mg extracts from Sf9 cells expressing wild-type hMutLα) was added. 
After incubation on an end-over-end shaker for 60 minutes at 4 °C, extracts were transferred into 
dispensable plastic columns (Bio-Rad). The columns were washed five times with 5 column 
volumes of cold buffer WB (300 mM NaCl, 10 % glycerol, 20 mM HEPES pH 8, 2 mM 2-
mercaptoethanol, 200 mM PMSF) containing 10 mM imidazol. Bound proteins were eluted with 5 
column volumes of buffer WB containing 100 mM imidazol and with 5 column volumes of buffer 
WB containing 200 mM imidazol. Fractions containing the highly purified MutLα variants were 
pooled, adjusted to 150 mM NaCl and concentrated on a 1 ml Resource-Q (AP Biotech) column. 
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Prior to the injection into the Resource-Q column, proteins were passed through a 6 ml Resource-S 
column to remove possible contaminants. After injection, the Resource-S column was removed and 
proteins were eluted with a raising 4 %/ml salt gradient. The fractions containing the pure proteins 
were pooled, dialysed extensively against storage buffer (20 mM HEPES pH=7.6, 0.1 mM EDTA, 
110 mM NaCl, 10 % sucrose, 2 mM 2-mercaptoethanol and 0.5 mM PMSF), and stored in 
aliquots at -80 ÚC.
Other Proteins- The purified hMutSα  was described previously (43,44).
UV Cross-l inking- An aliquot of purified protein (1 µg) was incubated for 30 minutes at 
4°C in 10 µl crosslinking buffer (50 mM Tris-HCl (pH=7.5), 6 mM MgCl2, 10 % glycerol, 10 % 
sucrose, 5 mM DTT, 0.2 mg/ml BSA and 0.5 µM [α-32P]-ATP). The samples were placed on ice, 
irradiated for 5 minutes in an UV-Stratalinker (STRATAGENE) and separated by 7.5 % SDS-
PAGE. Gels were extensively washed in fixing solution (30 % methanol, 10 % acetic acid) and 
analyzed by autoradiography.
Partial Proteolysis Experiments- In a final volume of 20 µl, 3 µg (16.5 pmol) of the 
recombinant proteins were  with 25 mM TrisCl (pH=8), 120 mM NaCl, 1 mM DTT in the presence 
or absence of 1 mM MgCl2. The ATP concentration was between 0 and 10 mM, as shown in Fig. 6. 
After a 15 minute pre-incubation at 20 ÚC, 10 ng of trypsin (Promega) were added and the reaction 
was allowed to proceed for 8 minutes at 20 ÚC. The reactions were stopped by the addition of 4 µl 
6x SDS loading dye and boiling for 5 minutes at 95 ÚC. The samples were loaded onto 10 % SDS 
polyacrylamide gels and the protein bands were visualised with Coomassie Blue.
ATPase Assays- The ATPase assays were carried out at 37 °C in a 15 µl reaction mix 
containing 20 mM TrisCl (pH=8), 120 mM NaCl, 5 mM MgCl2, 1 mM DTT, 400 µM cold ATP, 
222 nM [γ-32P]-ATP and 60 pmol purified protein (4 µM). To test the DNA-dependent stimulation 
of the hMutLα heterodimer, either an 81-mer single-stranded oligonucleotide (81BGTGT; final 
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concentration 12 µM) or a 3193 nucleotide long single-stranded and covalently closed phagemid 
DNA (pGEM-T; final concentrations 2, 20, or 200 nM) were added to the reactions (data not 
shown). At selected time points, 2 µl aliquots were removed and mixed with 5 µl formamide 
loading dye. 2 µl aliquots were loaded onto 20 % denaturing polyacrylamide gels, which were then 
exposed to Biomax MR films (KODAK). The bands were quantified using the ImageQuant Software 
v1.2 (MOLECULAR DYNAMICS, INC.). For the calculation of the Michaelis-Menten constants, 
the ATPase activity was measured in the presence of varying concentrations of cold ATP (200-1000
 µM).
In vitro MMR Assays – The MMR assays were carried out as described previously (45)159}. 
Briefly, cytoplasmic protein extracts were prepared from TK6 and HCT116 cell lines, using 5x108 
cells harvested in the exponential growth phase. After resuspension in ice-cold hypotonic buffer 
(20 mM HEPES pH=7.9, 5 mM KCl, 1.5 mM MgCl2, 0.1 mM PMSF, 1 mM DTT) at a density of 
1x108 cells/ml, the cells were allowed to swell for 10 minutes in a glass Dounce homogenizer on 
ice, and then lysed mechanically by applying four or more strokes with a tight pestle. When more 
than 80 % of cells were lysed, the nuclei were pelleted, the supernatant was centrifuged (12000 x g 
for 10 minutes at 4 ÚC) and stored in small aliquots at -80 ÚC.
Wild type and mutant M13mp2 phage used to generate the mismatch-containing 
heteroduplexes were kindly provided by Tom Kunkel. The heteroduplex DNA contained the 
indicated base/base mispair within the coding sequence of the lacZ α-complementation gene, and a 
nick either 5 or 3 from the mispair. 1 fmol of substrate was incubated with 50 µg of cytoplasmic 
extract, supplemented where necessary with 200 ng of the purified recombinant hMutLα variants. 
The repair reaction (25 µl) contained 30 mM HEPES pH=7.8, 7 mM MgCl2, 4 mM ATP, 200 µM 
each CTP, GTP and UTP, 100 µM each dATP, dCTP, dGTP and dTTP, 40 mM creatine phosphate, 
100 fmol creatine phosphokinase and 15 mM sodium phosphate pH=7.5. After 20 minutes of 
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incubation at 37 ÚC, the heteroduplex DNA was purified and electroporated into E.coli NR9162 
(mutS), plated on minimal medium in a soft agar layer containing 0.5 ml of a log culture of E.coli 
CSH50, 0.5 mg IPTG and 2 mg X-Gal. After incubation for 16 h at 37 ÚC, repair efficiency could 
be determined by analyzing the color of the plaques.
Bandshift Assays- The bandshift experiments were performed with either a 48mer 
heteroduplex oligonucleotide containing a 1 base insertion loop (∆1) or a homoduplex G/C. The 
substrates (80 fmol, 4 nM), hMutSα (75 nM) and hMutLα variants (150 nM) were incubated for 20 
minutes on ice in 20 µl binding buffer (20 mM HEPES pH=7.6, 1 mM DTT, 50 µg/ml BSA, 120 
mM NaCl, 1.75 ng/µl poly(dI-dC)•poly(dI-dC) (AP Biotech), 12.5 % Glycerol). If indicated, 2 mM 
MgCl2 and/or 0.5 mM ATP were added prior to the addition of the proteins. 2 mM EDTA was added 
to reactions, in which MgCl2 was omitted. If indicated, monoclonal antibodies against hMSH6 
(Serotec, 66H6, 0.2 µg/µl) or hMLH1 (Pharmingen, cat. 13291A, 0.05 µg/µl) were added 10 minutes 
after the start of the incubation. 5 µl of each sample was carefully loaded onto a 4 % non-denaturing 
polyacrylamide gel (acrylamide-bisacrylamide 37.5:1). Gels were run in TAE buffer (pH=7.5) at 4 
°C, and 32P-labeled protein-DNA complexes were visualized using a STORM phosphorimager 
(Molecular Dynamics Inc.). The homoduplex and ∆1 substrates were constructed by annealing the 
oligonucleotide 48_Homo or 48_∆1 with the complementary strand (48_Bottom) that was labeled at 
its 5’ end with 32P using the polynucleotide kinase. 
RESULTS
Rationale for mutational analysis of the ATP binding domains of hMutLα↑ Comparison of 
the primary amino acid sequences and the available crystal structures of the nucleotide binding 
domains of MutL, NgyrB and HSP90 revealed that the ATP binding sites, including all known 
catalytic residues, are highly conserved (16,19,46). According to the GHKL consensus motifs 
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(13,14), three invariant amino acids were selected for mutagenesis (Fig. 1a, red stars). Their choice 
was based on the recently determined structure of the amino terminal fragment of MutL in complex 
with the non-hydrolyzable ATP analogue ADPNP, which revealed the distinct contributions of these 
residues towards the ATPase function (16) (Fig. 2). In MutL, the base of the ATP nucleotide is 
bound in a deep hydrophobic pocket. The first residue, a polar Asp-58 lies at the bottom of this 
pocket and forms a direct hydrogen bond with the exocyclic amino group of the adenine base. In 
HSP90, substitution of the equivalent aspartate by alanine or asparagine completely abolished 
nucleotide binding and the in vivo function of the protein (21,47). The second residue, Asn-33 plays 
a crucial role in the binding of the Mg2+ ion, because its side chain contributes both directly and via 
a water molecule to the coordination of the metal ion. In GHLK ATPases the nucleotide adopts a 
kinked conformation and oxygen atoms from all three phosphates contribute to the coordination of 
the metal. Accordingly, MutL and HSP90 are unable to bind ATP in the absence of Mg2+ (16,19) 
and substitution of the equivalent asparagine residue in HSP90 completely abolished its ATPase 
activity (21). The third residue, Glu-29 is most likely involved in the activation of the catalytic water 
molecule. In agreement with its proposed role as a general base, substitution of this residue with 
alanine abolished the ATPase activity of MutL (16,17), HSP90 (47,48), and type II topoisomerases 
(18,49) with only little or no effect on the binding of the nucleotide.
In order to study the role of ATP binding and/or hydrolysis in the function of hMutLα, we 
used site-directed mutagenesis to generate variants of hMLH1 or hPMS2 that carried single amino 
acid substitutions in one of the three above sites (Fig. 2). The hMutLα variants studied here are the 
following: the ATP binding deficient double mutant hMutLα [hMLH1(D63N)/hPMS2(D70N)], 
designated LαDN/DN, the Mg2+ binding deficient double mutant hMutLα 
[hMLH1(N38A)/hPMS2(N45A)], designated LαNA/NA, and the catalytic site double mutant 
hMutLα [hMLH1(E34A)/hPMS2(E41A)], designated LαEA/EA. LαDN/WT and LαWT/DN indicate mixed 
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heterodimers where either the hMLH1 or the hPMS2 subunit contains the relevant substitution, 
respectively.
Expression of hMutLα can be severely affected by single amino acid substitutions in the ATP 
binding domains of its subunits - Detailed analysis of the crystal structure of the N-terminal MutL 
fragment or of modeled structures of the hMLH1 ATP binding domain suggested that none of the 
planned substitutions should affect the overall protein fold. We were therefore surprised to find that 
some of the amino acid changes, such as the substitution of Asp-63 in the ATP binding pocket of 
hMLH1(D63N), resulted in a dramatically reduced expression of the hMutLα variants containing 
this subunit (Fig. 3, lanes 2,4). This effect was caused presumably through destabilization of the 
mutated hMLH1 and the consequent degradation of hPMS2, which is labile in the absence of the 
hMLH1 subunit (37). Interestingly, the equivalent substitution (D70N) in the hPMS2 subunit had no 
apparent effect on protein expression (lane 3). Sequencing of the expression constructs and detection 
of the full-length hMLH1 protein in these extracts by Western blotting ruled out the possibility that 
the reduced expression was due to additional mutations, which might have caused the premature 
truncation of the proteins (data not shown). In order to rule out an artifact inherent to the baculovirus 
system, we also analyzed this substitution in a homologous expression system, based on human 293T 
cells, which do not express hMLH1 (50). Co-transfection of these cells with vectors encoding either 
wild type or mutant hMLH1 and hPMS2 proteins also lead to a drastic reduction of the expression 
levels of hMutLα, when the hMLH1 subunit carried the D63N substitution (data not shown).
 Mutation of the asparagine involved in coordination of the Mg2+ ion had a deleterious effect on the 
expression of hMutLα only if both subunits carried the alanine substitution in their ATP binding 
pockets (Fig. 3, lane 7). Because identical titers of the baculovirus encoding hMLH1(N38A) were 
used for the parallel production of LαNA/WT and LαNA/NA, the difference in expression levels 
cannot be attributed to differences in the multiplicity of infection or in the quality of the insect cells 
used in the experiment. Our results suggest, therefore, that ATP binding by hMLH1 and, to a lower 
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extent also by hPMS2, is critical for the stable expression of the hMutLα heterodimer.
In contrast to the mutants described above, substitution of the catalytic residues in hMLH1 (E34A) or in hPMS2 
(E41A) affected neither the expression nor the stability of the proteins (Fig. 3, lane 8-9). Given that these latter mutants 
still bind ATP [ref. (51), see also Fig. 6] our results suggest that ATP binding, but not hydrolysis, is required for the 
stabilization of hMutLα.
Purification of the hMutLα variants- In order to facilitate the purification of the hMutLα 
variants, all hPMS2 expression vectors were modified to include an amino-terminal (His)6 tag. 
These vectors were co-expressed with the untagged hMLH1 in Sf9 cells and the resulting 
heterodimers were purified by a three-step procedure including chromatography on Ni-NTA (Fig. 4, 
see Experimental Procedures). The fact that the untagged hMLH1 variants co-purified with the 
(His)6-hPMS2 variants in an equimolar ratio implies that the ATP binding domains are unlikely to be 
involved in the regulation of the stable dimerization of the carboxy-terminal domains of hMLH1 and 
hPMS2 (36,38). However, the poor expression of the hMLH1(D63N) variant precluded the 
purification of the LαDN/WT and LαDN/DN heterodimers. In addition, the LαNA/NA variant was 
expressed in low amounts and could not be purified to the same extent as the others. This protein 
preparation contained a contaminant, which migrated slightly slower than hMLH1 in SDS-PAGE 
(Fig. 4). Although the contaminating protein did not appear to interfere with our assays, the results of 
experiments in which it was used were interpreted with caution.
ATP cross-linking reveals an inherent asymmetry of the two ATP binding sites of hMutLα -
 We used UV cross-linking to study the ATP binding properties of the hMutLα variants. Surprisingly, 
while the hMLH1 subunit of the wild type hMutLα complex was efficiently cross-linked to 
[α32P]ATP, only little radioactivity was found associated with the hPMS2 subunit (Fig. 5). In agreement 
with the extensive interaction between the three phosphate groups of the nucleotide and the Mg2+ 
ion observed in all structures of the GHLK ATPases, UV crosslinking of ATP to the hMLH1 subunit 
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showed an absolute requirement for Mg2+. Correspondingly, substitution of the Mg2+ co-ordinating 
 asparagine with alanine greatly reduced ATP cross-linking efficiency to the hMLH1 (N38A) mutant 
(Fig. 5). These results indicate that hMLH1 and hPMS2 bind the nucleotide with substantially 
different affinities, and could be explained in two ways. Either by the binding of the nucleotide in the 
hMLH1 subunit and not in hPMS2, or by the substantially longer residence times of the bound ATP 
molecule within the nucleotide binding pocket of hMLH1, which results in more efficient cross-
linking. In an attempt to understand which of these two possibilities applies, we carried out partial 
proteolysis experiments and ATP hydrolysis assays. 
ATP binding brings about a conformational change in hMLH1 that is detectable by partial 
proteolysis  We incubated the wild type hMutLα heterodimer with or without ATP in the presence of 
trypsin. In the absence of the nucleotide, the two polypeptides were degraded to numerous peptide 
fragments, ranging from ~60 to ~33 kDa and this pattern was retained also in the presence of low 
(0.1 and 1 µM) ATP concentrations (Fig. 6a). However, in the presence of 10 µM ATP a novel band 
of about 39 kDa appeared (Fig. 6, arrowed) and persisted up to an ATP concentration of 10 mM. 
Interestingly, no other major differences were detected in the peptide pattern.  This suggests that one 
of the hMutLα subunits bound ATP at a concentration of ~10 µM and above, and that this binding 
event resulted in a conformational change, which altered its proteolytic pattern. The results of the 
ATP cross-linking experiments suggested that the polypeptide in question should be hMLH1. This 
was confirmed through the partial proteolysis of the LαNA/wt and Lαwt/NA variants. The latter 
heterodimer produced a tryptic peptide pattern that was identical to the wild type hMutLα. In 
contrast, the LαNA/wt variant, in which the ATP binding site of MLH1 was mutated, failed to give 
rise to the 39 kDa proteolytic band (Fig. 6b). We were able to confirm the identity of the band also in 
LC/MS/MS experiments (data not shown), where it was unambiguously assigned to the N-terminus 
of hMLH1, as one of its tryptic peptides corresponded to amino acid residues 10-18 (RLDETVVN) 
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of this protein.
As can be seen in Fig. 6b, the 39 kDa proteolytic fragment of hMLH1 only appears in the 
presence of both ATP and Mg2+. This finding further confirms that the binding of the nucleotide is 
absolutely dependent on the presence of the divalent metal cation, as was shown for MutL (16) and 
HSP90 (19). The partial proteolysis experiments further showed that the EA mutation in the catalytic 
site of the hMLH1 subunits does not affect nucleotide binding, as the ATP-dependent 39 kDa tryptic 
band was present in all three variants, LαWT/WT, LαEA/WT and LαEA/EA (Fig. 6c). 
The ATPase activity of hMutLα is very low and is not stimulated by single stranded DNA 
 The ATPase activity of the highly-purified wild type hMutLα is very low. Our semi-quantitative 
estimates put the ATPase activity of wild type hMutLα in a similar range as that of MutL, i.e. ~0.5 
min-1 (16,24) and our data not shown. As anticipated, the ATPase activity of the LαEA/EA 
heterodimer was very close to background. Interestingly, mutations in the ATP catalytic site of 
hMLH1 and hPMS2 had different effects. Thus, while the hMLH1 mutant LαEA/wt displayed an 
ATPase activity that was intermediate between the wild type and the double mutant factors, the 
activity of the Lαwt/EA variant was severely attenuated, being close to that of LαEA/EA (Fig. 7).
In contrast to its prokaryotic homologue (17), the ATPase activity of the wild type hMutLα 
complex was not stimulated by the addition of single-stranded DNA (81-mer oligonucleotide or 3.2 
kb phagemid; data not shown).
Substitutions in the ATP binding domains of hMLH1 and hPMS2 affect the biological 
activity of hMutLα in in vitro MMR assay to similar extents  We tested the biological activity of the 
hMutLα variants in an in vitro MMR assay, in which the recombinant proteins were used to 
complement the MMR-deficient extract of HCT116 cells that lack hMutLα (37). As shown in Fig. 8, 
no repair of heteroduplex plasmid substrates containing a nick located either 5 or 3 from a single GT 
mismatch was observed after 20 minutes of incubation with the HCT116 extracts. In contrast, more 
18
than 80% of the substrate were repaired if wild type hMutLα (200 ng) was added to these extracts. 
Titration experiments revealed that the MMR complementation efficiency of the His-tagged 
hMutLα was quantitatively indistinguishable from that of an untagged hMutLα complex (data not shown and 
(37)). Moreover, since removal of the His-tag by the TEV protease did not change the 
complementation efficiency of the heterodimer (data not shown), we concluded that the presence of 
the His-tag on the hPMS2 subunit did not have any effect on the biological activity of hMutLα.
Substitution of the catalytic glutamate residue affected the in vitro MMR activity of hMutLα 
to different extents. Thus, while the catalytic double mutant was inactive in the complementation 
assay, the variants carrying the substitution in only one subunit displayed intermediate levels of 
MMR activity. Importantly, repair from both the 5 or 3’ direction was affected to a similar extent, 
regardless of which subunit carried the substitution. These results clearly demonstrate that although 
the ATPase activities of both subunits are required for efficient MMR, the process can still function, 
albeit less efficiently, when only one subunit can hydrolyze the nucleotide. This was not the case 
when the ATP binding ability of the hMutLα subunits was affected; in this case, already a single 
subunit mutation resulted in the loss of complementation activity, which implies that ATP binding by 
both subunits is required for MMR.
ATP stimulates the formation of a ternary complex between hMutLα, hMutSα and DNA -
 The interaction between purified hMutLα and hMutSα on mismatched DNA was investigated in 
bandshift assays using a 48-mer homoduplex (G/C), or a similar 48/49-mer heteroduplex substrate 
containing a single nucleotide insertion in one strand (Fig. 9, left panel). In the presence of hMutSα, 
a specific protein/DNA complex (*) was formed, which dissociated upon the addition of 0.5 mM 
ATP or ATP"Mg2+ (see also (43)). However, while ATP brought about the dissociation of hMutSα 
from the oligonucleotide substrate, it promoted the formation of a ternary complex (**) between the 
oligonucleotide, hMutSα and hMutLα. This species appears to contain both heterodimers, as addition 
of anti-hMSH6, anti-hMLH1 or anti-hPMS2 antibodies resulted in a further retardation of the 
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complex (***). Interestingly, formation of the ternary complex was dependent on the presence of 
ATP, but not magnesium. As hMutLα does not undergo an ATP-driven conformational change in 
the absence of the metal ion (Fig. 6b), we concluded from these experiments that interaction of the 
hMutSα and hMutLα heterodimers requires ATP binding, but not hydrolysis, in the hMutSα factor. 
These results support and extend the findings reported for the S. cerevisiae MutSα and MutLα 
homologues (52-54).
Mutations in the ATP binding domains of hMutLα do not affect the formation of the ternary 
complex with hMutSα on DNA  The ATP-dependent interaction between hMutLα and hMutSα 
observed in the bandshift experiments might reflect the recruitment of hMutLα to the hMutSα- 
bound mispair at a very early step during the repair reaction. We were therefore interested to see 
whether the in vitro complementation defect of the hMutLα variants was caused by their inability to 
interact with the hMutSα complex. As shown in Fig. 9 (right panel), all of the hMutLα variants that 
we were able to purify in sufficient amounts were able to form the ternary complexes (**), which 
suggests that the nucleotide dependence of the ternary complex formation is not dictated by the 
hMutLα heterodimer. (NB: The supershifted band in lane 7 of the right panel of Fig. 9 due to 
LαNA/NA is weaker than that observed in the other lanes. This is not due to the reduced ability of the 
protein to form a ternary complex, but rather to the lower amounts of the heterodimer used in this 
experiment. See also legend to Fig. 9.) Taken together, our results suggest that the deleterious effect 
of the substitutions in the ATP binding sites of hMutLα is linked to a step downstream from the 
recruitment of the heterodimer to the DNA-bound hMutSα complex.
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DISCUSSION
Despite the identification of several MutL homologues in the human genome, the 
hMLH1/hPMS2 heterodimer hMutLα plays the predominant role in postreplicative MMR. This is 
witnessed primarily by the fact that human tumor cell lines carrying mutations in either gene have 
mutator phenotypes of similar magnitude (32,34). As this shows that both subunits of hMutLα are 
equally important for MMR, the finding that the hPMS2 gene was only extremely rarely mutated in 
HNPCC families was unexpected and implied either that the two genetic loci are differentially 
susceptible to mutagenesis, or that mutations in hPMS2 are phenotypically silent. The results of our 
present investigation tend to support the former hypothesis, as they revealed major differences in the 
effects that the seemingly equivalent mutations had on the two polypeptides. Thus, the conservative 
substitution of an aspartate by an asparagine within the NBDs of hMLH1 and hPMS2 was 
anticipated to have no effect on the folding of the polypeptides. This expectation was based on the 
finding that the HSP90(D93N) mutant could be shown to retain its structural fold (47) and was 
substantiated in the case of the hMutLα variant carrying the D70N mutation in the ATP binding 
domain of hPMS2, which was expressed with an efficiency similar to wild type. Unexpectedly, the 
D63N mutation that abolished ATP binding in the hMLH1 subunit deleteriously affected the 
expression efficiency of the heterodimer (Fig. 3), similarly to observations made with hMutLα 
variants carrying missense mutations identified in HNPCC families that mapped close to the ATP 
binding site of hMLH1 (Fig. 1b,(50,52,55)). This effect may be linked with an increased 
susceptibility of the mutated protein to degradation, as suggested by experiments where ATP binding 
was shown to protect the amino terminus of the S. cerevisiae MLH1 against proteolysis (51). These 
results demonstrated that the ability to stably bind ATP is essential for the stability of hMLH1 but 
not hPMS2, and implied that the two polypeptides may have different affinities for the nucleotide, 
despite the conservation of their NBDs. This latter prediction could be substantiated by the greater 
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efficiency of  [α-32P]-ATP cross-linking to hMLH1 (Fig. 5). We postulate that the ATP binding 
site of hMLH1 needs to be occupied at physiological ATP concentrations, and thus that it is 
adversely affected by the absence of the nucleotide, while the ATP binding deficient variant of 
hPMS2 would not be destabilized, as this protein does not appear to require bound ATP for correct 
folding or stabilization against proteolysis. Given the importance of ATP binding to hMLH1 
stability, it was surprising to see that the LαNA/WT variant was expressed at levels similar to the 
wild type protein. This phenomenon could be explained if we assume that the affinity of this variant 
for ATP was strongly reduced, but not eliminated. In this scenario, the low level of ATP binding 
observed in the UV cross-linking experiments (Fig. 5) might be sufficient to stabilize the protein, 
but too low to support its biological activity (see also below). 
Interestingly, while the ATP cross-linking (Fig. 5) and partial proteolysis (Fig. 6) 
experiments implied that the hMLH1 subunit of hMutLα bound the nucleotide with higher affinity, 
attenuation of ATP binding in the hPMS2 subunit affected the ATPase activity of the heterodimer to 
a greater extent than did the same mutation in the hMLH1 subunit. These findings suggest that 
hPMS2 is catalytically more active than hMLH1 and that the ATP residence times of the nucleotide 
in the ATP binding pocket of hPMS2 might be too short for efficient cross-linking or for effective 
protection from trypsin. These findings are supported by those of Yang and colleagues (56), who 
demonstrated that the isolated N-terminal domain of hPMS2 has ATPase activity.
In order to test how the observed differences in ATPase activities of the two hMutLα 
subunits affected the biological activity of the hMutLα variants under study, we tested the 
recombinant factors in in vitro MMR assays. As anticipated, the LαEA/EA and LαNA/NA double 
mutants that were unable to hydrolyze or bind ATP, respectively, were unable to complement the 
hMutLαdeficient extracts of HCT116 cells (Fig. 8). The same was true for the single subunit mutants 
that were deficient in nucleotide binding. These results show that ATP binding in both subunits is 
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essential for MMR. Surprisingly, the LαWT/EA and LαEA/WT hMutLα variants, in which the 
hydrolytic capacity was attenuated in one or the other subunit, displayed significant, but similar 
reductions in MMR efficiency. This result was unexpected, given that the ATPase activities of the 
two heterodimers were affected by the respective mutations to different extents, and implied that 
hMutLα must be able to hydrolyse ATP in order to be active in MMR, but that the activity can be 
extremely low  (Fig. 8). Interestingly, we made a similar observation when we mutated the ATP 
binding sites of the hMSH2 and hMSH6 subunits of hMutSα (43). While the latter subunit 
contributed more towards the ATPase activity of the heterodimer, the effect of mutations in hMSH2 
and hMSH6 on mismatch repair efficiency in vitro was similar. 
While this study was in progress, the mutator phenotypes of knock-in S. cerevisiae strains 
carrying mutations within the ATPase domains of MLH1 or PMS1 (the functional homologue of 
hPMS2) were described (51). The substitutions altered amino acids corresponding to the catalytic 
glutamates or to invariant glycine residues located in the respective phosphate binding loops of the 
proteins (Motif III in Figs. 1 and 2), and were predicted – similarly to our study – to abolish 
nucleotide hydrolysis or nucleotide binding, respectively. In agreement with our results, the strain in 
which both genes carried a substitution of the catalytic glutamate residue displayed a strong mutator 
phenotype, while mutation of only a single MutLα subunit produced a weaker mutator effect. 
However, in the yeast system, the mlh1 single mutant was more affected than the corresponding
 pms1 variant, and this functional asymmetry became even more pronounced for mutants that carried 
the glycine to alanine substitutions: the mlh1-G98A strain showed a full mutator phenotype 
comparable to a MMR-deficient strain, while the pms1-G128A strain was only a very weak 
mutator. This latter finding cannot be easily explained. Our results showed that ATP binding is more 
important than ATP hydrolysis and similar data were reported for “heterodimeric” topoisomerase II 
variants (57-59) mentioned above. Thus, assuming that the G128A mutation in the P-loop motif of 
the S. cerevisiae protein abolished ATP binding, the mutator phenotype of the pms1-G128A strain 
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would have been expected to be stronger than that of the PMS1 mutant deficient in ATP hydrolysis. 
The discrepancy between our results and those generated by Liskay and colleagues suggests that 
mutation of the conserved glycine within the P-loop of the yeast PMS1 protein gave rise to a 
complex phenotype, which cannot be explained simply by the loss of nucleotide binding.
 The functional asymmetry observed with the yeast MutLα was suggested to reflect an unequal 
contribution of the two subunits towards the repair events with a 5→3 or a 3→5 directionality (51). 
Such an interpretation would require the two MutLα subunits to interact with different downstream 
factors and the two ATP binding domains to act independently of each other. We addressed this 
question by comparing the repair efficiencies of the single mutants on substrates that contained the 
nick either on the 5’ or the 3’ side of the mismatch. The finding that these substitutions affected 
MMR from both directions to a similar extent implies that the above hypothesis does not apply to the 
human system and that the two ATP binding domains of hMutLα act in an interdependent way. 
Evidence for such a coordinated function is provided by genetic analysis (60) and by elegant two 
hybrid experiments carried out with the N-terminal fragments of yeast MutLα (51), which clearly 
showed that ATP binding at both subunits is required in order for the nucleotide binding domains to 
dimerize. Assuming that the carboxy-termini of the full-length proteins remain stably associated, 
the function of the amino-termini could be to form an ATP-driven molecular clamp, which then 
interacts with the downstream MMR factors.
Taken together, the data presented in this study allowed us to propose a model for hMutLα 
function, in which ATP binding operates a molecular clamp formed by the NBDs of its two subunits. 
The ATP binding site of the hMLH1 subunit might be mostly occupied, while that of the hPMS2 
subunit might oscillate between the bound and the unbound form and thus ensure that the clamp does 
not close stably. Interaction with DNA and/or other MMR proteins (e.g. mismatch-bound hMutSα) 
might alter the nucleotide binding properties of the ATP binding pocket of the hPMS2 subunit, 
which could result in closing of the clamp and in immobilization of hMutLα at its site of action. The 
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heterodimer might then be recycled by the hydrolysis of the nucleotides, which would lead to 
opening and release of the clamp. This mode of action would explain the MMR phenotype of all our 
mutants. While variants unable to bind ATP at one or both of their subunits would fail to close the 
clamp, the catalytic double mutants might be MMR deficient, because their clamp would remain 
closed. The partial defect in MMR of the single catalytic mutants could also be explained if we 
assume that ATP hydrolysis catalyzed by only one subunit might be sufficient to induce the 
dissociation of the amino-termini and thus to recycle the repair factor, but more slowly.
The biological role of the MutL homologues has been frequently described as that of 
“molecular matchmakers”. Studies carried out with the prokaryotic MutL suggest that it functions as 
a bridging molecule that transmits signals from the mismatch-bound MutS to the downstream 
factors. MutL could be shown to interact with the DNA helicase II and to load it at the site of the 
nick, where the process of exonucleolytic degradation of DNA is initiated. This nick was introduced 
into the DNA by MutH, the endonucleolytic activity of which could be correspondingly shown to be 
activated by MutL in a reaction that requires ATP binding, but not hydrolysis (4,16). This activation 
is even more efficient in the presence of MutS and a mismatched substrate, but in this case it requires 
ATP hydrolysis. That the ATPase activity of MutL is involved was shown by the inability of the 
MutL mutant (E29A), which binds ATP but fails to hydrolyze it, to bring about the full, MutS-
dependent activation of MutH (4,5,16,61). Although the mechanism of strand discrimination in 
eukaryotes differs from that of E. coli, the role of the eukaryotic MutL homologues lies most likely 
in controlling protein/protein interactions, as in the prokaryotic system. In eukaryotic cells, 
biochemical studies suggested that MutSα and MutLα interact on DNA in an ATP-dependent
 manner (53,62,63). The human factors are capable of similar interactions (Fig. 9 and (64)). 
Interestingly, our study shows that because the ternary complexes were formed between hMutSα and 
all the hMutLα variants, their formation could not be driven by ATP binding within the hMutLα 
component. This prediction was further substantiated by the formation of the MutSα"MutLα"DNA 
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complexes in the absence of magnesium, i.e. under experimental conditions where hMutLα does not 
bind ATP. It would therefore appear that the association of hMutSα,  hMutLα and mismatched DNA 
is driven by ATP binding within hMutSα, as this heterodimer was shown previously to undergo an 
ATP-driven conformational change that was independent of nucleotide hydrolysis (44). Although 
the supershift experiments leave many questions open, they show that the hMutLα variants studied 
here retained their overall structures, such that they were still able to interact with DNA-bound 
hMutSα. We therefore conclude that the observed lack of activity of these proteins in our in vitro 
MMR assay must be due to their failure to interact with components of the MMR machinery that are 
downstream from mismatch recognition, such as PCNA and/or EXO1 (54,60).
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FIGURE LEGENDS
FIG. 1. a, Conserved sequence motifs that constitute the ATP binding pockets of GHL ATPases. Left 
panel: Structure-based alignment of the amino-terminal sequences of MutL (E.coli), hMLH1, 
hPMS2, Gyrase B (E.coli) and human HSP90 reveals the presence of four highly-conserved motifs 
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(I-IV, red). Red stars indicate amino acid residues that were substituted in this study. The secondary 
structures of the nucleotide-bound proteins are schematically drawn above the sequence alignment.
 Right panel: Ribbon diagram of the MutL (1-349) crystal structure in complex with ADPNP. The 
polypeptide folds into two globular domains (amino acids 20-220 and 224-331). Motifs I-IV (red) 
mark the site of ATP binding within the first domain (see also Fig. 2). Note that only one subunit of 
the dimeric protein complex is shown. (The figure was prepared using file 1b63 from the 
Brookhaven Protein Data Bank (PDB) (17)). b, Clustering of HNPCC germline mutations in the
 hMLH1 gene. All hMLH1 single amino acid substitutions reported in the HNPCC database were 
aligned along the primary sequence of hMLH1. Amino acid substitutions shown in red gave rise to 
low expression in other functional assays (50,52,55). (?) indicates that the pathogenicity of the 
substitution is uncertain, due to incomplete segregation data or because the variant was proficient in 
a functional assay. Green boxes indicate regions conserved in all MutL homologues. Red boxes 
indicate the four conserved motifs that constitute the ATP binding pocket of hMLH1. Blue boxes 
indicate regions that are conserved among eukaryotic MLH1 homologues. These regions have been 
implicated in the interaction with the respective PMS homologues (36,38). 
FIG. 2. ATP binding pocket of MutL. Amino acids from the four conserved motifs (I-IV, red) are 
shown in ribbon representation. Left panel: Structure of the nucleotide-free protein. Helix A (Motif 
I) harbors the catalytic base (Glu-29) and the asparagine residue (Asn-33) that is involved in the 
coordination of the Mg2+ ion. Motif II and IV are part of an extended β-sheet. Asp-58 sticks out 
from this β-sheet to form a H-bond with the bound nucleotide. Note that helix D (Motif III) 
occupies the ATP binding pocket and has to unfold in order for the nucleotide to gain access to its 
binding site. Center panel: Structure of the protein in complex with ADPNP. In the presence of the 
nucleotide, the amino-terminal part of helix D unfolds to form a flexible loop involved in the 
binding of the phosphate groups (P-Loop). ADPNP and Mg2+ are shown in gray and green, 
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respectively, and water molecules are shown as blue spheres. Right panel: Amino acid substitutions 
introduced into hMLH1 and hPMS2, respectively. (The figure was prepared using the files 1BKN
 (left) and 1b63 (center) from the Brookhaven PDB). 
FIG. 3. Expression of hMutLα variants in baculovirus-infected Sf9 cells. Sf9 cells were co-infected 
with baculovirus vectors encoding either wild type or mutant forms of the untagged hMLH1 and 
hPMS2 proteins as indicated above the panel (see text for abbreviations). Total cell extracts (20 µg)
 were the separated on a 7.5 % SDS polyacrylamide gel and stained with Coomassie Blue. Note that a 
very abundant band migrated with the same size as hMLH1 (compare extracts of infected vs. non-
infected cells shown in lane 10).
FIG. 4. Purity of the hMutLα variants used in this study. Purified hMutLα variants (2 µg) were 
separated on a 12 % SDS polyacrylamide gel and stained with Coomassie Blue. Note that hMLH1 
runs as a doublet on these gels, as previously reported (37). Due to the low expression levels, 
LαNA/NA was obtained only in a partially-purified form in low amounts (approximately 0.5 µg loaded; 
see text for details). LαDN/WT and LαDN/DN could not be purified.
FIG. 5. UV crosslinking of [α-32P]-ATP to hMutLα variants. Purified hMutLα variants (1 µg) were 
incubated with [α-32P]-ATP. After short UV irradiation, the proteins were separated on a 7.5 % 
SDS polyacrylamide gel. Left panel, Gel stained with Coomassie Blue. Right panel, Autoradiograph 
of the same gel. A faint band was detected at the height of hPMS2 after very long exposures (data 
not shown).
FIG. 6. ATP and magnesium binding induce a conformational change in the hMLH1 subunit. a, 3 µg
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 of purified wild type hMutLα were incubated with increasing concentrations of ATP and 1 mM Mg2+ 
for 15 minutes at 20 ÚC. The proteins were then partially digested with 10 ng trypsin for further 8 
minutes at 20 ÚC and the tryptic peptides were separated on 10 % SDS polyacrylamide gels and 
visualized with Coomassie Blue. The proteolytic fragment appearing in the presence of >10 µM ATP 
is marked with an arrow. b, Appearance of the 39 kDa proteolytic fragment (arrow) is dependent on 
the presence of ATP and magnesium. The fragment was absent from the partial tryptic digest of 
LαNA/WT, which is unable to bind ATP in the active site of the hMLH1 subunit. This suggests that the 
fragment originates from the latter polypeptide (see text for details).
FIG. 7. ATPase activity of hMutLα. Purified LαWT/WT or the catalytic single or double mutants 
LαEA/WT, LαWT/EA and LαEA/EA (4 µM) were incubated with 400 µM [γ-32P]-ATP. After the 
indicated time, the samples were separated on 20 % denaturing polyacrylamide gels, exposed to 
Biomax MR film and the bands were quantitated using the ImageQuant software (Molecular 
Dynamics, Inc.). The assay was performed in triplicate using three independent preparations of the 
recombinant proteins (error bars show the standard deviation from the mean).
FIG. 8. ATPase activity of hMutLα is required for mismatch correction. Purified hMutLα variants 
(200 ng) were used to complement extracts of mismatch repair-deficient HCT116 cells. The 
substrates were M13 heteroduplexes carrying a G/T mispair and a strand discrimination signal (a 
nick) either 3 or 5 from the mismatch (see Experimental Procedures). Similar results were obtained 
when the HCT116 extracts were supplemented with extracts from Sf9 cells over-expressing the 
hMutLα variants, ruling out the possibility that the mismatch repair activity of the mutant 
heterodimers was lost during the purification procedure (data not shown). Because the repair activity 
of various MMR deficient cell lines fluctuates between 0 and 25% in this assay (data not shown), 
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levels below 25% are scored as MMR deficient 
FIG. 9. Interaction of hMutLα variants with hMutSα on heteroduplex DNA. Left panel, Bandshift 
analysis performed with wild type hMutSα (75 nM) and hMutLα (150 nM), using 32P-labeled 48-
mer homoduplex G/C or a 48/49-mer heteroduplex oligonucleotide  containing a one nucleotide IDL 
(4 nM). Where indicated, monoclonal antibodies against hMSH6 (1) or against hMLH1 (2) were 
added to the reactions. The free substrate was separated from protein-bound complexes on 4 % 
native polyacrylamide gels, which were then analyzed on a STORM PhosphoImager using the 
ImageQuant software (Molecular Dynamics, Inc.). Where indicated, reactions contained 2 mM 
MgCl2 and/or 0.5 mM ATP. Right panel, Bandshift analysis carried out with hMutLα variants. All reactions 
contained wild type hMutSα (75 nM), the indicated hMutLα variants (150 nM) and 0.5 mM ATP. 
MgCl2 was omitted from all reactions. Note that due to the low concentration of the purified protein, 
the reaction in lane 7 contained only 75 nM LαNA/NA. However, the presence of the band, albeit 
only a weak one, at the height of the supershift (**) suggests that also this mutant was able to interact 
with DNA-bound hMutSα.
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